# ARTICLE

# Reporting summary

Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper.

# Data availability

All relevant data supporting the key findings of this study are available within the article and its Supplementary Information files. Data underlying Fig. 5c and Supplementary Fig. 2 are provided as a Source data file. Data underlying all the other figures are provided in Supplementary Data and data repositories: LifeLines-Deep cohort [https://www.ebi.ac.uk/ega/datasets/EGAD00001001991], 1000 IBD cohort [https://www.ebi.ac.uk/ega/datasets/EGAD00001004194], 300OB cohort [https://ega-archive.org/dacs/EGAC00001001143], and 500FG cohort [https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA319574]. The iHMP data are available via https://ibdmdb.org/tunnel/public/summary.html. Due to informed consent regulation, the data sets of the Lifelines-DEEP, IBD, 300OB and 500FG cohorts are available upon request to the University Medical Center of Groningen (UMCG), Lifelines and Radboud University Medical Center, respectively. This includes the submission of a letter of intention to the corresponding data access committee [the Lifelines Data Access Committee for the LifeLines-DEEP data (Jackie Dekens, e-mail: j.a.m.dekens@umcg.nl), 1000 IBD Data access Committee UMCG for the IBD data (Melinde E. Wijers, e-mail: m.e.wijers@umcg.nl) and the Human Functional Genomics Data Access Committee for 500FG and 300OB data (Martin Jaeger, e-mail: Martin.Jaeger@radboudumc.nl)]. Data sets can be made available under a data transfer agreement and the data usage access is subject to local rules and regulations. Source data are provided with this paper.

# Code availability

For this study, the following software was used: kneadData (v0.4.6.1), Bowtie2 (v2.1.0), MetaPhlAn2 (v2.7.2), HUMAnN2 (v0.10.0), SparCC Python package, R (v3.5.2), SpiecEasi R package (v1.0.6), and meta R package (v4.9.5). Code used for generating the microbial abundance profiles is publicly available at https://github.com/GRONINGEN-MICROBIOME-CENTRE/Groningen-Microbiome/blob/master/Scripts/Metagenomics_pipeline_v1.md. Code used for the statistical analyses is publicly available at https://github.com/GRONINGEN-MICROBIOME-CENTRE/Groningen-Microbiome/tree/master/Projects/Microbial%20co-abundance%20network. Source data are provided with this paper.

# Received

6 December 2019; Accepted: 20 July 2020; Published online: August 2020

# References

1. Chen, L. M., Garmaeva, S., Zhernakova, A., Fu, J. Y. & Wijmenga, C. A system biology perspective on environment-host-microbe interactions. Hum. Mol. Genet. 27, R187–R194 (2018).
2. Falony, G. et al. Population-level analysis of gut microbiome variation. Science 352, 560–564 (2016).
3. Zhernakova, A. et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 352, 565–569 (2016).
4. Lloyd-Price, J. et al. Strains, functions and dynamics in the expanded Human Microbiome Project. Nature 550, 61–66 (2017).
5. Kurilshikov, A., Wijmenga, C., Fu, J. & Zhernakova, A. Host genetics and gut microbiome: challenges and perspectives. Trends Immunol. 38, 633–647 (2017).
6. Wu, H. et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat. Med. 23, 850–858 (2017).
7. Grasset, E. et al. A specific gut microbiota dysbiosis of type 2 diabetic mice induces GLP-1 resistance through an enteric NO-dependent and gut-brain axis mechanism. Cell Metab. 26, 278 (2017).
8. Fu, J. et al. The gut microbiome contributes to a substantial proportion of the variation in blood lipids. Circ. Res. 117, 817–824 (2015).
9. Jie, Z. et al. The gut microbiome in atherosclerotic cardiovascular disease. Nat. Commun. 8, 845 (2017).
10. Liu, R. et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat. Med. 23, 859–868 (2017).
11. Bouter, K. E., van Raalte, D. H., Groen, A. K. & Nieuwdorp, M. Role of the gut microbiome in the pathogenesis of obesity and obesity-related metabolic dysfunction. Gastroenterology 152, 1671–1678 (2017).
12. Halfvarson, J. et al. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat. Microbiol. 2, 17004 (2017).
13. Imhann, F. et al. Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. Gut 67, 108–119 (2018).
14. Vich Vila, A. et al. Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. Sci. Transl. Med. 10, eaap8914 (2018).
15. Imhann, F. et al. Proton pump inhibitors affect the gut microbiome. Gut 65, 740–748 (2016).
16. Mangalam, A. et al. Human gut-derived commensal bacteria suppress CNS inflammatory and demyelinating disease. Cell Rep. 20, 1269–1277 (2017).
17. Petriz, B. A. & Franco, O. L. Metaproteomics as a complementary approach to gut microbiota in health and disease. Front. Chem. 5, 4 (2017).
18. Rosshart, S. P. et al. Wild mouse gut microbiota promotes host fitness and improves disease resistance. Cell 171, 1015.E13–1028.E13 (2017).
19. Surana, N. K. & Kasper, D. L. Moving beyond microbiome-wide associations to causal microbe identification. Nature 552, 244–247 (2017).
20. Baumler, A. J. & Sperandio, V. Interactions between the microbiota and pathogenic bacteria in the gut. Nature 535, 85–93 (2016).
21. Eickhoff, M. J. & Bassler, B. L. SnapShot: bacterial quorum sensing. Cell 174, 1328 (2018).
22. Schirmer, M. et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell 167, 1897 (2016).
23. Berry, D. & Widder, S. Deciphering microbial interactions and detecting keystone species with co-occurrence networks. Front. Microbiol. 5, 219 (2014).
24. Banerjee, S., Schlaeppi, K. & van der Heijden, M. G. A. Keystone taxa as drivers of microbiome structure and functioning. Nat. Rev. Microbiol. 16, 567–576 (2018).
25. Faust, K. et al. Microbial co-occurrence relationships in the human microbiome. PLoS Comput. Biol. 8, e1002606 (2012).
26. Xia, L. C., Ai, D., Cram, J., Fuhrman, J. A. & Sun, F. Efficient statistical significance approximation for local similarity analysis of high-throughput time series data. Bioinformatics 29, 230–237 (2013).
27. Reshef, D. N. et al. Detecting associations in large data sets. Science 334, 1518–1524 (2011).
28. Deng, Y. et al. Molecular ecological network analyses. BMC Bioinformatics 13, 113 (2012).
29. Friedman, J. & Alm, E. J. Inferring correlation networks from genomic survey data. PLoS Comput. Biol. 8, e1002687 (2012).
30. Faust, K. et al. Microbial co-occurrence relationships in the human microbiome. PLoS Comput. Biol. 8, e1002606 (2012).
31. Biagi, E. et al. Gut microbiota and extreme longevity. Curr. Biol. 26, 1480–1485 (2016).
32. Flemer, B. et al. Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut 66, 633–643 (2017).
33. Wang, J. et al. Dysbiosis of maternal and neonatal microbiota associated with gestational diabetes mellitus. Gut 67, 1614–1625 (2018).
34. Gevers, D. et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe 15, 382–392 (2014).
35. Yilmaz, B. et al. Microbial network disturbances in relapsing refractory Crohn’s disease. Nat. Med. 25, 323–336 (2019).
36. Rottjers, L. & Faust, K. Can we predict keystones? Nat. Rev. Microbiol. 17, 193–193 (2019).
37. Banerjee, S., Schlaeppi, K. & van der Heijden, M. G. A. Reply to ‘Can we predict microbial keystones?’. Nat. Rev. Microbiol. 17, 194–194 (2019).
38. Kurtz, Z. D. et al. Sparse and compositionally robust inference of microbial ecological networks. PLoS Comput. Biol. 11, e1004226 (2015).
39. Schirmer, M., Garner, A., Vlamakis, H. & Xavier, R. J. Microbial genes and pathways in inflammatory bowel disease. Nat. Rev. Microbiol. 17, 497–511 (2019).
40. Musher, D. M. in Medical Microbiology 4th edn (ed. Baron, S.) Ch. 30 (The University of Texas Medical Branch at Galveston, Galveston, TX, 1996).
41. Doyuk, E., Ormerod, O. J. & Bowler, I. C. J. W. Native valve endocarditis due to Streptococcus vestibularis and Streptococcus oralis. J. Infect. 45, 39–41 (2002).
42. Pimenta, F. et al. Streptococcus infantis, Streptococcus mitis, and Streptococcus oralis strains with highly similar cps5 loci and antigenic relatedness to serotype 5 pneumococci. Front. Microbiol. 9, 3199 (2018).
43. Niu, C. S. et al. Decrease of plasma glucose by allantoin, an active principle of yam (Dioscorea spp.), in streptozotocin-induced diabetic rats. J. Agric. Food Chem. 58, 12031–12035 (2010).
44. Tsai, C. C. et al. Allantoin activates imidazoline I-3 receptors to enhance insulin secretion in pancreatic beta-cells. Nutr. Metab. 11, 41 (2014).
45. Marlier, J. F., Cleland, W. W. & Zeczycki, T. N. Oxamate is an alternative substrate for pyruvate carboxylase from Rhizobium etli. Biochemistry 52, 2888–2894 (2013).
46. Hall, V. Actinomyces–gathering evidence of human colonization and infection. Anaerobe 14, 1–7 (2008).
47. Smith, E. & Morowitz, H. J. Universality in intermediary metabolism. Proc. Natl Acad. Sci. USA 101, 13168–13173 (2004).
48. Fenn, K. et al. Quinones are growth factors for the human gut microbiota. Microbiome 5, 161 (2017).